US0167444019 - Common Stock
ALLARITY THERAPEUTICS INC
NASDAQ:ALLR (12/20/2024, 8:00:00 PM)
After market: 1.0097 +0.02 (+1.98%)0.9901
-0.04 (-3.87%)
Allarity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2021-12-21. Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The firm is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. The company has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS
P: 14014264664
Employees: 6
Website: https://allarity.com/
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to...
Here you can normally see the latest stock twits on ALLR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: